All In Biotech

NDA 007073 · Pfizer

Azulfidine En-Tabs

Sulfasalazine · Oral · Aminosalicylate

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1950

Jun 20, 1950

Approved uses

1

Original approval plus efficacy supplements

Registered trials

104

33 Phase 3, 14 recruiting

FAERS reports

78,454

65,745 serious, 7,496 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 12, 2026.

INDICATIONS AND USAGE Sulfasalazine tablets are indicated: in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; and for the prolongation of the remission period between acute attacks of ulcerative colitis

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 20, 1950 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • AZULFIDINE EN-TABS · SULFASALAZINE 500MG · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB
  • AZULFIDINE · SULFASALAZINE 500MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Sulfasalazine" as an intervention, any sponsor and status, largest first.

All 104 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective29,490
  • rheumatoid arthritis19,666
  • pain16,091
  • drug intolerance13,852
  • arthralgia13,600
  • fatigue13,447
  • joint swelling12,846
  • off label use11,276
  • rash11,118
  • abdominal discomfort10,166
  • contraindicated product administered9,780
  • condition aggravated9,702

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004636
2005614
2006684
2007832
2008843
2009829
2010870
20111,147
20121,441
20131,324
20141,510
20152,401
20163,318
20175,227
20186,253
20197,389
202011,228
20217,186
20227,151
20235,138
20245,753
20254,579
20262,100

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Azulfidine (Sulfasalazine)

2024 spending

$232K

Beneficiaries

171

532 claims

Per beneficiary

$1,358

$1.73 per unit

View as table
YearSpending
2020$387,390
2021$579,871
2022$433,431
2023$272,281
2024$232,222

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 561 on PubMed

Sponsor: Pfizer · Also marketed as Azulfidine

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.